DOI QR코드

DOI QR Code

위암의 수술 중 방사선치료의 결과

The Results of Intraoperative Radiotherapy for Stomach Cancer

  • 최지훈 (영남대학교 의과대학 방사선종양학교실) ;
  • 강민규 (영남대학교 의과대학 방사선종양학교실) ;
  • 김명세 (영남대학교 의과대학 방사선종양학교실) ;
  • 김성규 (영남대학교 의과대학 방사선종양학교실) ;
  • 윤상모 (영남대학교 의과대학 방사선종양학교실) ;
  • 김성훈 (영남대학교 의과대학 방사선종양학교실)
  • Choi, Ji-Hoon (Department of Radiation Oncology, Yeungnam University College of Medicine) ;
  • Kang, Min-Kyu (Department of Radiation Oncology, Yeungnam University College of Medicine) ;
  • Kim, Myung-Se (Department of Radiation Oncology, Yeungnam University College of Medicine) ;
  • Kim, Sung-Kyu (Department of Radiation Oncology, Yeungnam University College of Medicine) ;
  • Yun, Sang-Mo (Department of Radiation Oncology, Yeungnam University College of Medicine) ;
  • Kim, Sung-Hoon (Department of Radiation Oncology, Yeungnam University College of Medicine)
  • 투고 : 2010.04.26
  • 심사 : 2010.05.13
  • 발행 : 2010.06.30

초록

목 적: 본 연구는 위암 환자에서 근치적 수술과 수술 중 방사선치료(intraoperative radiotherapy)를 시행한 장기 추적 결과를 보고하고자 한다. 대상 및 방법: 1988년부터 1994년까지, 51명의 원발성 국소진행성 위암 환자에게 근치적 수술과 수술 중 방사선치료를 시행하였다. 수술 후 외부방사선치료는 30명의 환자에서, 보조 항암화학요법은 35명의 환자에서 시행되었다. 수술 중 방사선치료는 9 MeV의 전자선을 이용하여 15 Gy를 조사하였으며, 외부방사선치료 조사선량의 중앙값은 43.2 Gy (7.2~45 Gy)이었다. 보조 항암화학요법은 35명에서 시행되었다. 추적관찰기간의 중앙값은 64개월(1~254개월)이었다. 결 과: 환자의 나이는 30~71세(중앙값, 58세)였다. American Joint Committee on Cancer (AJCC) tumor-notemetastasis (TNM) 병기(2002)는 병기 I 13명(25.5%), 병기 II 10명(19.6%), 병기 III 25명(49.0%), 병기 IV 3명(5.9%) 이었다. 주된 재발은 원격전이로 11명이었으며, 이 중 1명에서 국소재발이 동시에 발견되었다. 전체 환자의 5년 국소영역제어율, 무병생존율, 전체생존율은 각각 94.7%, 66.5%, 51.7%이었다. 다변량분석에서 전체생존율에 영향을 주는 인자에는 나이, TNM 병기, 외부방사선치료가 있었으며, 무병생존율에 대해서는 TNM 병기만이 유의한 인자였다. 결 론: 국소 진행성 위암에서 근치적 수술과 수술 중 방사선치료로 높은 국소제어율을 얻을 수 있었다. 그러나 수술 중 방사선치료의 생존율에 대한 영향에 대해서는 연구가 더 필요할 것으로 생각된다.

Purpose: We retrospectively analyzed the long-term results of radical surgery and intraoperative radiation therapy (IORT) in patients with stomach cancer. Materials and Methods: From 1988 to 1994, 51 patients were treated with curative surgery and IORT. Postoperative external beam radiotherapy (EBRT) was administered to 30 patients, while adjuvant chemotherapy was administered to 35 patients. A dose of 15 Gy was irradiated with a 9 MeV electron beam as the IORT and a median dose of EBRT was 43.2 Gy (range, 7.2 to 45 Gy). The follow-up period ranged from 1~254 months, with a median follow-up period of 64 months. Results: The median age of all the patients was 58 years (range, 30 to 71 years). The distribution of pathologic stage (American Joint Committee on Cancer [AJCC] 2002 tumor-note-metastasis [TNM]) was as follows: 13 stage I (25.5%), 10 stage II (19.6%), 25 stage III (49.0%), and 3 stage IV (5.9%). Distant metastases occurred in 11 patients (10 in the peritoneum and 1 in bone), including one patient with concurrent local recurrence (anastomosis site). The 5-year locoregional control, disease free survival and overall survival rates were 94.7%, 66.5%, and 51.7%, respectively. For the multivariate analysis, age, TNM stage, and EBRT were significant prognostic factors for overall survival, and only TNM stage for disease free survival. Conclusion: We could have achieved a high loco-regional control rate in patients with locally advanced stomach cancer by adding IORT to radical surgery. However, the benefit of IORT on survival remains to be elucidated.

키워드

참고문헌

  1. Gunderson LL, Sosin H. Adenocarcinoma of the stomach: areas of failure in a re-operation series (second or symptomatic look) clinicopathologic correlation and implications for adjuvant therapy. Int J Radiat Oncol Biol Phys 1982;8:1-11
  2. Sindelar WF, Kinsella TJ, Tepper JE, et al. Randomized trial of intraoperative radiotherapy in carcinoma of the stomach. Am J Surg 1993;165:178-186 https://doi.org/10.1016/S0002-9610(05)80423-4
  3. Fu S, Lu JJ, Zhang Q, Yang Z, Peng L, Xiong F. Intraoperative radiotherapy combined with adjuvant chemoradiotherapy for locally advanced gastric adenocarcinoma. Int J Radiat Oncol Biol Phys 2008;72:1488-1494 https://doi.org/10.1016/j.ijrobp.2008.03.012
  4. Abe M, Shibamoto Y, Ono K, Takahashi M. Intraoperative radiation therapy for carcinoma of the stomach and pancreas. Front Radiat Ther Oncol 1991;25:258-269
  5. Abe M, Nishimura Y, Shibamoto Y. Intraoperative radiation therapy for gastric cancer. World J Surg 1995;19:544-547
  6. Ogata T, Araki K, Matsuura K, et al. A 10-year experience of intraoperative radiotherapy for gastric carcinoma and a new surgical method of creating a wider irradiation field for cases of total gastrectomy patients. Int J Radiat Oncol Biol Phys 1995;32:341-347 https://doi.org/10.1016/0360-3016(94)00479-5
  7. Skoropad VY, Berdov BA, Mardynski YS, Titova LN. A prospective, randomized trial of pre-operative and intraoperative radiotherapy versus surgery alone in resectable gastric cancer. Eur J Surg Oncol 2000;26:773-779 https://doi.org/10.1053/ejso.2000.1002
  8. Kim MS, Kang CH, Kim SK, Song SK, Kwan KB, Kim HD. IORT in gastric cancer. J. Korean Soc Ther Radiol 1991;9:87-92
  9. Kim MS, Kim SK, Song SK, et al. Intraoperative radiation therapy (IORT) in locally advanced gastric and colorectal cancer. J Korean Cancer Assoc 1992;24:596-603
  10. Kim MS, Kim SK, Song SK, Kim HJ, Kwan KB, Kim HD. Complication of intraoperative radiation therapy (IORT) in gastric cancer. J Korean Soc Ther Radiol 1992;10:187-192
  11. Gunderson LL, Willet CG, Harrison LB, Calvo FA. Intraoperative irradiation: techniques and results. Totowa, NJ; Humana Press, 1999:180-181
  12. Abe M, Takahashi M, Yabumoto E, Onoyama Y, Torizuka K. Techniques, indications and results of intraoperative radiotherapy of advanced cancers. Radiology 1975;116: 693-702 https://doi.org/10.1148/116.3.693
  13. Calvo FA, Aristu JJ, Azinovic I, et al. Intraoperative and external radiotherapy in resected gastric cancer: updated report of a phase II trial. Int J Radiat Oncol Biol Phys 1992;24: 729-736 https://doi.org/10.1016/0360-3016(92)90721-S
  14. Martinez-Monge R, Calvo FA, Azinovic I, et al. Patterns of failure and long-term results in high-risk resected gastric cancer treated with postoperative radiotherapy with or without intraoperative electron boost. J Surg Oncol 1997;66: 24-29 https://doi.org/10.1002/(SICI)1096-9098(199709)66:1<24::AID-JSO6>3.0.CO;2-P
  15. Drognitz O, Henne K, Weissenberger C, et al. Longterm results after intraoperative radiation therapy for gastric cancer. Int J Radiat Oncol Biol Phys 2008;70:715-721 https://doi.org/10.1016/j.ijrobp.2007.07.2331
  16. Qin HL, Lin CH, Zhang XL. Evaluation of intraoperative radiotherapy for gastric carcinoma with D2 and D3 surgical resection. World J Gastroenterol 2006;12:7033-7037 https://doi.org/10.3748/wjg.v12.i43.7033
  17. Coquard R, Ayzac L, Gilly FN, et al. Intraoperative radiation therapy combined with limited lymph node resection in gastric cancer: an alternative to extended dissection? Int J Radiat Oncol Biol Phys 1997;39:1093-1098 https://doi.org/10.1016/S0360-3016(97)00386-6
  18. Macdonald JS, Smalley SR, Benedetti J, et al. Chemoradiotherapy after surgery compared with surgery alone for adenocarcinoma of the stomach or gastroesophageal junction. N Engl J Med 2001;345:725-730 https://doi.org/10.1056/NEJMoa010187
  19. S, Lim DH, Lee J, et al. An observational study suggesting clinical benefit for adjuvant postoperative chemoradiation in a population of over 500 cases after gastric resection with D2 nodal dissection for adenocarcinoma of the stomach. Int J Radiat Oncol Biol Phys 2005;63:1279-1285 https://doi.org/10.1016/j.ijrobp.2005.05.005
  20. Cunningham D, Allum WH, Stenning SP, et al. Perioperative chemotherapy versus surgery alone for resectable gastroesophageal cancer. N Engl J Med 2006;355:11-20 https://doi.org/10.1056/NEJMoa055531
  21. Sakuramoto S, Sasako M, Yamaguchi T, et al. Adjuvant chemotherapy for gastric cancer with S-1, an oral fluoropyrimidine. N Engl J Med 2007;357:1810-1820 https://doi.org/10.1056/NEJMoa072252